Chronic erosive herpes simplex virus infection of the penis in a human immunodeficiency virus-positive man, treated with imiquimod and famciclovir [11]

British Journal of Dermatology

Volumn 147, Issue 5, 2002, Pages 1034-1036

  Danielsen, A G ^a   Petersen, C S ^b   Iversen, J ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; FOSCARNET; IMIQUIMOD; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; SULFADIAZINE SILVER; VALACICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFECT; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE COUNT; MALE; PENIS; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME; VIRUS IDENTIFICATION; VIRUS LOAD;

2-AMINOPURINE; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMINOQUINOLINES; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HERPES GENITALIS; HUMANS; MALE; PENILE DISEASES;

EID: 0036436931     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.504412.x     Document Type: Letter

References (10)

1. Severson JL, Tyring SK. Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol 1999; 135: 1393-7.
2. Straus SE, Smith HA, Brichman C et al. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med 1982; 96: 270-7.
3. Safrin S, Crumpacker C, Chatis P et al. A controlled trial comparing foscarnet with vidarabine for acylovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991; 325: 551-5.
4. Miller RL, Imbertson LM, Reiter MJ, Gerster JF. Treatment of herpes simplex virus infection in guinea pigs by imiquimod. Antiviral Res 1999; 44: 31-42.
5. Wagner TL, Ahonen CL, Couture AM et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999; 191: 10-19.
6. Testerman TL, Gerster JF, Imbertson LM et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995; 58: 365-72.
7. Imbertson LM, Beaurline JM, Couture AM. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110: 734-9.
8. Burns RP, Ferbel B, Tomai M et al. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000; 94: 13-23.
9. Suzuki H, Wang B, Shivji GM et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-41.
10. Gilbert J, Drehs MM, Weinberg JM. Topical imiquimod for aciclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol 2001; 137: 1015-7.